AbCellera (ABCL) announced it has received a No Objection Letter from Health Canada authorizing its clinical trial application for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. The Phase 1 study is anticipated to begin in Q3 and will evaluate ABCL635’s safety, pharmacokinetics, and pharmacodynamics in healthy participants and postmenopausal women with moderate-to-severe VMS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera Wins Patent Appeal Against Bruker
- AbCellera says Federal Circuit rejects Bruker Cellular’s invalidity challenge
- AbCellera Biologics: Promising Antibody Discovery with Strong Liquidity and Strategic Partnerships
- AbCellera Biologics Navigates Progress and Challenges in Earnings Call
- AbCellera price target lowered to $8 from $10 at Stifel